BCO vs DBD: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BCO and DBD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BCO and DBD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

The Brink's Company (NYSE: BCO) runs one of the world's largest secure logistics networks, moving and managing cash and valuables across roughly 50 countries. Its legacy business is armored transport, cash-in-transit, money processing, and international valuables logistics for banks, retailers, mints, and jewelers. Layered on top are two faster-growing recurring-revenue lines: ATM Managed Services (AMS), where Brink's owns or operates a bank's ATM fleet end to end, and Digital Retail Solutions (DRS), where a smart safe in a retail store counts and credits cash to the merchant's account before the armored truck arrives. Management has reported 14 consecutive quarters of double-digit organic growth in the combined AMS and DRS business, and those two lines now carry a materially higher margin and lower churn than the traditional route business.

Full BCO guide

Diebold Nixdorf makes the machines that move cash and check out shoppers: ATMs, cash recyclers, self-checkout systems, point-of-sale terminals, and kiosks, sold through two segments (Banking and Retail) alongside the Vynamic software suite and a large installed-base services business. It is the global leader in self-checkout shipments outside China and serves a majority of the world's largest banks and retailers, so its revenue is tied to bank branch modernization, cash-recycling adoption, and retail automation cycles rather than any single fast-growing end market.

Full DBD guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BCO drivers: ATM Managed Services and Digital Retail Solutions; The NCR Atleos acquisition.
• DBD drivers: Services mix and recurring revenue; DN Series recyclers and margin uplift.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Leverage is the dominant risk: Brink's already carries ~$4.56 billion of total debt against ~$1.66 billion of cash, and financing a $6.6 billion acquisition on a ~$4.6 billion equity base would push the balance sheet considerably further, with an Altman Z-Score of ~1.67 flagging balance-sheet strain even before the deal. For DBD, the core hardware markets (ATMs, POS, self-checkout) are mature and grow at low single digits, so structural declines in cash usage and bank branch counts are a persistent headwind.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BCO if you believe its drivers more; DBD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BCO and DBD guides.

BCO. The wide gap between the ~25.9x trailing GAAP multiple and the ~11.6x forward multiple reflects both non-recurring charges in reported earnings and the earnings contribution analysts expect once NCR Atleos is consolidated. On enterprise value the stock screens cheaper than the equity multiple suggests, at ~8.4x EBITDA, because ~$2.9 billion of net debt sits above the equity. The ~0.9% dividend yield with a ~24% payout ratio leaves room for coverage, though capital allocation after the acquisition will likely favor debt reduction.

DBD. DBD trades around a $2.9 to $3.0 billion market cap with the stock near the mid-$80s, well above its August 2023 relisting price of about $20.57. Valuation multiples reflect a re-rated turnaround: revenue growth is modest (low single digits) but free cash flow and margins have improved markedly since emergence. The reported P/E near the high-20s is elevated for a mature hardware company, so the market is pricing in continued margin and cash-flow expansion rather than top-line acceleration.

Headline figures (approximate, August 2026): BCO shows revenue (ttm) ~$5.48B, up ~8% year over year, net income (ttm) ~$181M, EPS ~$4.32, market cap / enterprise value ~$4.6B / ~$7.5B, p/e trailing vs forward ~25.9x vs ~11.6x; DBD shows revenue (ttm) ~$3.86B, q1 2026 revenue ~$888M (+6% YoY), 2026 adj. ebitda guidance ~$510M to $535M, 2026 adj. eps guidance ~$5.25 to $5.75.

BCO and DBD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BCO and DBD exposure against your real portfolio. It is not an investment adviser.